4.3 Article

Optical scattering as an early marker of apoptosis during chemotherapy and antiangiogenic therapy in murine models of prostate and breast cancer

期刊

NEOPLASIA
卷 23, 期 3, 页码 294-303

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neo.2021.01.005

关键词

Imaging; Spectroscopy; Optical scattering; Treatment monitoring; Apoptosis; Cell proliferation

类别

资金

  1. Department of Defense [W81XWH-15-1-0070]
  2. American Cancer Society [RSG14-014-01-CCE]

向作者/读者索取更多资源

Monitoring tumor response to treatment in real time using spatial frequency domain imaging (SFDI) shows promise as a noninvasive and label-free method to quantify changes in tissue optical scattering. This optical technique may serve as an early predictive biomarker of treatment response, outperforming traditional parameters such as tumor volume or functional parameters like oxygen saturation.
Monitoring of the in vivo tumor state to track therapeutic response in real time may help to evaluate new drug candidates, maximize treatment efficacy, and reduce the burden of overtreatment. Current preclinical tumor imaging methods have largely focused on anatomic imaging (e.g., MRI, ultrasound), functional imaging (e.g., FDG-PET), and molecular imaging with exogenous contrast agents (e.g., fluorescence optical tomography). Here we utalize spatial frequency domain imaging (SFDI), a noninvasive, label-free optical technique, for the wide-field quantification of changes in tissue optical scattering in preclinical tumor models during treatment with chemotherapy and antiangiogenic agents. Optical scattering is particularly sensitive to tissue micro-architectural changes, including those that occur during apoptosis, an early indicator of response to cytotoxicity induced by chemotherapy, thermotherapy, cryotherapy, or radiation therapy. We utilized SFDI to monitor responses of PC3/2G7 prostate tumors and E0771 mammary tumors to treatment with cyclophosphamide or the antiangiogenic agent DC101 for up to 49 days. The SFDI-derived scattering amplitude was highly correlated with cleaved caspase-3, a marker of apoptosis (rho(p) = 0.75), while the exponent of the scattering wavelength-dependence correlated with the cell proliferation marker PCNA (rho(p) = 0.69). These optical parameters outperformed tumor volume and several functional parameters (e.g., oxygen saturation and hemoglobin concentration) as an early predictive biomarker of treatment response. Quantitative diffuse optical scattering is thus a promising new early marker of treatment response, which does not require radiation or exogenous contrast agents.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据